344 related articles for article (PubMed ID: 28579617)
1. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
2. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
3. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.
Johnson DP; Spitz GS; Tharkar S; Quayle SN; Shearstone JR; Jones S; McDowell ME; Wellman H; Tyler JK; Cairns BR; Chandrasekharan MB; Bhaskara S
Oncotarget; 2015 Mar; 6(7):4863-87. PubMed ID: 25605023
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin.
Alikarami F; Safa M; Faranoush M; Hayat P; Kazemi A
Biomed Pharmacother; 2017 Oct; 94():1077-1093. PubMed ID: 28821159
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
6. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.
McClellan JS; Dove C; Gentles AJ; Ryan CE; Majeti R
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):4074-9. PubMed ID: 25775523
[TBL] [Abstract][Full Text] [Related]
9. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M
J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517
[TBL] [Abstract][Full Text] [Related]
10. Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines.
Yao C; Zhang G; Walker A; Zhao KY; Li Y; Lyu L; Tang Y; Ru P; Jones D; Zhao W
Leuk Res; 2017 Sep; 60():129-134. PubMed ID: 28818808
[TBL] [Abstract][Full Text] [Related]
11. An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.
Lickliter JD; Taylor K; Szer J; Grigg A; Arthur C; Hughes TP; Durrant S; Filshie R; Irving I; Seldon M; Ellacott J; Boyd AW; D'Rozario J; Rooney K; Lynch K; Bradstock K;
Leuk Lymphoma; 2015 Mar; 56(3):630-8. PubMed ID: 24844361
[TBL] [Abstract][Full Text] [Related]
12. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
13. Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
Miller K; Webster J; Imus P; Ament C; Hardy M; Zou YS
Cancer Genet; 2023 Jun; 274-275():30-32. PubMed ID: 36966724
[TBL] [Abstract][Full Text] [Related]
14. ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia.
Behrens K; Brajanovski N; Xu Z; Viney EM; DiRago L; Hediyeh-Zadeh S; Davis MJ; Pearson RB; Sanij E; Alexander WS; Ng AP
Sci Adv; 2024 Mar; 10(10):eadj8803. PubMed ID: 38457494
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
17. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
19. Acute lymphoblastic leukaemia with an e1a3 BCR-ABL1 fusion.
Langabeer SE; Haslam K; Kelly J; Leahy M; Vandenberghe E
Acta Haematol; 2011; 126(4):214-5. PubMed ID: 21934295
[No Abstract] [Full Text] [Related]
20. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
